PFO tamponade is an effective and safe vitreous substitute

Article

The perfluoro-n-octane (PFO) tamponade is a safe and effective short-term vitreous substitute in primary rhegmatogenous retinal detachment repair

The perfluoro-n-octane (PFO) tamponade is a safe and effective short-term vitreous substitute in primary rhegmatogenous retinal detachment repair, reveals a study in Retina

Dr Ryan Rush and his team, Sydney Eye Hospital, Australia, retrospectively analysed the charts of 39 eyes at 2-24 postoperative months after primary PFO retention. The second replacement was evaluated for anatomical attachment rates, visual acuity gain and postoperative complications.

The results demonstrated that 33 of 39 eyes had four or more retinal breaks - 31 of these eyes had at least one inferior break and 12 presented with preoperative proliferative vitreoretinopathy.

PFO was retained without posturing and all eyes showed full anatomical retinal attachment after primary vitrectomy for at least 7-17 days. The final anatomical success rate was 92.4% after perfluoropropane gas or siicone oil PFO exchange.

Visual acuity improved from 2.07 ± 0.86 to 0.76 ± 0.79 logarithm of the minimum angle of resolution in macula-off and 0.11 ±0.08 to 0.12 ± 0.09 logarithm of the minimum angle of resolution in macula-on rhegmatogenous retinal detachment eyes.

Posterior capsular opacification was greatly increased due to PFO retention, without affecting the final retinal attachment success rate. The highest reattachment rates were made when perfluoropropane or silicone oil was swapped for PFO.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.